Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06685978 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

Name: Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands — clinical trial record (NCT06685978)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorTasly Pharmaceutical Group Co., Ltd

Started2024-04-26

View on ClinicalTrials.gov ↗

Record status

This record was last updated November 13, 2024 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Tasly Pharmaceutical Group Co., Ltd

19 trials monitored

See 1 trial at risk

This study will evaluate the efficacy and Safety of Xiangjurupining Capsule in the treatment of Hyperplasia of Mammary Glands(stagnation of liver-qi and phlegm).

Trial Details

NCT Number	NCT06685978
Lead Sponsor	Tasly Pharmaceutical Group Co., Ltd
Conditions	Hyperplasia of Mammary Glands
Enrollment	430 participants
Start Date	2024-04-26
Primary Completion	2026-04-30 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-13